MiMedx Group Inc Share Price OTC Bulletin Board
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- | - |
04-30 | Transcript : MiMedx Group, Inc., Q1 2024 Earnings Call, Apr 30, 2024 | |
04-30 | Earnings Flash (MDXG) MIMEDX GROUP Posts Q1 Revenue $84.7M, vs. Street Est of $79.4M | MT |
Sales 2024 * | 361M 0 28.69B | Sales 2025 * | 406M 0 32.24B | Capitalization | 1.16B 0 92.33B |
---|---|---|---|---|---|
Net income 2024 * | 45M - 3.57B | Net income 2025 * | 55M - 4.37B | EV / Sales 2024 * | 3.22 x |
Net cash position 2024 * | - - 0 | Net cash position 2025 * | - - 0 | EV / Sales 2025 * | 2.86 x |
P/E ratio 2024 * |
25.1
x | P/E ratio 2025 * |
19
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.76% |
Latest transcript on MiMedx Group Inc
Managers | Title | Age | Since |
---|---|---|---|
Joe Capper
CEO | Chief Executive Officer | 60 | 26/01/23 |
Douglas Rice
DFI | Director of Finance/CFO | 58 | 04/07/23 |
John R. Harper
CTO | Chief Tech/Sci/R&D Officer | - | 31/05/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
William Hawkins
BRD | Director/Board Member | 70 | 01/07/20 |
Phyllis Gardner
BRD | Director/Board Member | 73 | 07/03/21 |
K. Newton
BRD | Director/Board Member | 61 | 18/06/19 |
1st Jan change | Capi. | |
---|---|---|
-20.42% | 125M | |
+2.15% | 75.19M | |
+3.39% | 58.55M | |
+5.05% | 57.06M | |
-2.99% | 50.8M |